

Robin J Shattock

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4758647/robin-j-shattock-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

134
papers

4,886
citations

36
h-index

65
g-index

147
ext. papers

6,000
ext. citations

7.5
avg, IF

5.69
L-index

#	Paper	IF	Citations
134	Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial.. <i>EClinicalMedicine</i> , 2022 , 44, 101262	11.3	8
133	Presentation of antigen on extracellular vesicles using transmembrane domains from viral glycoproteins for enhanced immunogenicity.. <i>Journal of Extracellular Vesicles</i> , 2022 , 11, e12199	16.4	1
132	Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimers.. <i>Npj Vaccines</i> , 2022 , 7, 44	9.5	0
131	Use of Chlamydial Elementary Bodies as Probes to Isolate Pathogen-Specific Human Monoclonal Antibodies. <i>Methods in Molecular Biology</i> , 2021 , 2183, 19-28	1.4	
130	Isolating Pathogen-Specific Human Monoclonal Antibodies (hmAbs) Using Bacterial Whole Cells as Molecular Probes. <i>Methods in Molecular Biology</i> , 2021 , 2183, 9-18	1.4	
129	Early Colorectal Responses to HIV-1 and Modulation by Antiretroviral Drugs. <i>Vaccines</i> , 2021 , 9,	5.3	2
128	SARS-CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (React 2): diagnostic accuracy study. <i>BMJ, The</i> , 2021 , 372, n423	5.9	24
127	Innate Inhibiting Proteins Enhance Expression and Immunogenicity of Self-Amplifying RNA. <i>Molecular Therapy</i> , 2021 , 29, 1174-1185	11.7	10
126	Quality by design modelling to support rapid RNA vaccine production against emerging infectious diseases. <i>Npj Vaccines</i> , 2021 , 6, 65	9.5	9
125	Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice. <i>Nature Communications</i> , 2021 , 12, 2893	17.4	54
124	Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP). <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 2129-2136 ⁰	5.1	136 ⁰
123	Willingness to participate in COVID-19 vaccine trials; a survey among a population of healthcare workers in Uganda. <i>PLoS ONE</i> , 2021 , 16, e0251992	3.7	5
122	Knowledge, Attitudes, and Practices Regarding COVID-19 among Healthcare Workers in Uganda: A Cross-Sectional Survey. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	5
121	The entry inhibitor DS003 (BMS-599793): a BMS-806 analogue, provides superior activity as a pre-exposure prophylaxis candidate. <i>Aids</i> , 2021 , 35, 1907-1917	3.5	1
120	Effect of complexing lipids on cellular uptake and expression of messenger RNA in human skin explants. <i>Journal of Controlled Release</i> , 2021 , 330, 1250-1261	11.7	13
119	Interplay of diverse adjuvants and nanoparticle presentation of native-like HIV-1 envelope trimers. <i>Npj Vaccines</i> , 2021 , 6, 103	9.5	1
118	Immunogenicity of stabilized HIV-1 Env trimers delivered by self-amplifying mRNA. <i>Molecular Therapy - Nucleic Acids</i> , 2021 , 25, 483-493	10.7	3

117	Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines. <i>Journal of Controlled Release</i> , 2021 , 338, 201-210	11.7	11
116	Ornithine-derived oligomers and dendrimers for in vitro delivery of DNA and ex vivo transfection of skin cells via saRNA. <i>Journal of Materials Chemistry B</i> , 2020 , 8, 4940-4949	7.3	9
115	Precisely targeted gene delivery in human skin using supramolecular cationic glycopolymers. <i>Polymer Chemistry</i> , 2020 , 11, 3768-3774	4.9	4
114	The , , and Effect of Polymer Hydrophobicity on Charge-Reversible Vectors for Self-Amplifying RNA. <i>Biomacromolecules</i> , 2020 , 21, 3242-3253	6.9	10
113	Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. <i>Nature Communications</i> , 2020 , 11, 3523	17.4	216
112	Mannosylated Poly(ethylene imine) Copolymers Enhance saRNA Uptake and Expression in Human Skin Explants. <i>Biomacromolecules</i> , 2020 , 21, 2482-2492	6.9	20
111	Big Is Beautiful: Enhanced saRNA Delivery and Immunogenicity by a Higher Molecular Weight, Bioreducible, Cationic Polymer. <i>ACS Nano</i> , 2020 , 14, 5711-5727	16.7	47
110	Resources, Production Scales and Time Required for Producing RNA Vaccines for the Global Pandemic Demand. <i>Vaccines</i> , 2020 , 9,	5.3	31
109	The complex challenges of HIV vaccine development require renewed and expanded global commitment. <i>Lancet, The</i> , 2020 , 395, 384-388	4.0	26
108	Rapid development and deployment of high-volume vaccines for pandemic response. <i>Journal of Advanced Manufacturing and Processing</i> , 2020 , 2, e10060	2.7	24
107	A targeted reactivation of latent HIV-1 using an activator vector in patient samples from acute infection. <i>EBioMedicine</i> , 2020 , 59, 102853	8.8	5
106	Chemokine-Adjuvanted Plasmid DNA Induces Homing of Antigen-Specific and Non-Antigen-Specific B and T Cells to the Intestinal and Genital Mucosae. <i>Journal of Immunology</i> , 2020 , 204, 903-913	5.3	4
105	Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 seroprevalence survey. <i>Thorax</i> , 2020 , 75, 1082-1088	7.3	85
104	An improved synthesis of poly(amidoamine)s for complexation with self-amplifying RNA and effective transfection. <i>Polymer Chemistry</i> , 2020 , 11, 5861-5869	4.9	2
103	RNA Vaccines: A Suitable Platform for Tackling Emerging Pandemics?. <i>Frontiers in Immunology</i> , 2020 , 11, 608460	8.4	23
102	-Depleted Vaginal Microbiota in Pregnant Women Living With HIV-1 Infection Are Associated With Increased Local Inflammation and Preterm Birth. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020 , 10, 596917	5.9	4
101	Antigenicity and immunogenicity of HIV-1 gp140 with different combinations of glycan mutation and V1/V2 region or V3 crown deletion. <i>Vaccine</i> , 2019 , 37, 7501-7508	4.1	3
100	Induction of innate cytokine responses by respiratory mucosal challenge with R848 in zebrafish, mice, and humans. <i>Journal of Allergy and Clinical Immunology</i> , 2019 , 144, 342-345.e7	11.5	4

99	Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence. <i>Nature Communications</i> , 2019 , 10, 2355	17.4	68
98	Effects of cationic adjuvant formulation particle type, fluidity and immunomodulators on delivery and immunogenicity of saRNA. <i>Journal of Controlled Release</i> , 2019 , 304, 65-74	11.7	22
97	The Skin You Are In: Design-of-Experiments Optimization of Lipid Nanoparticle Self-Amplifying RNA Formulations in Human Skin Explants. <i>ACS Nano</i> , 2019 , 13, 5920-5930	16.7	29
96	Envelope-Specific Recognition Patterns of HIV Vaccine-Induced IgG Antibodies Are Linked to Immunogen Structure and Sequence. <i>Frontiers in Immunology</i> , 2019 , 10, 717	8.4	5
95	Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial. <i>Lancet Infectious Diseases</i> , 2019 , 19, 1091-1100	25.5	48
94	Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA. <i>Gene Therapy</i> , 2019 , 26, 363-372	4	73
93	Identification of potential biomarkers of vaccine inflammation in mice. <i>ELife</i> , 2019 , 8,	8.9	14
92	The Safety and Immunogenicity of GTUMultiHIV DNA Vaccine Delivered by Transcutaneous and Intramuscular Injection With or Without Electroporation in HIV-1 Positive Subjects on Suppressive ART. <i>Frontiers in Immunology</i> , 2019 , 10, 2911	8.4	3
91	Emerging Technologies for Low-Cost, Rapid Vaccine Manufacture. <i>Biotechnology Journal</i> , 2019 , 14, e1809376	10.76	36
90	A heterogeneous human immunodeficiency virus-like particle (VLP) formulation produced by a novel vector system. <i>Npj Vaccines</i> , 2018 , 3, 2	9.5	13
89	Localized cyclical variations in immunoproteins in the female genital tract and the implications on the design and assessment of mucosal infection and therapies. <i>American Journal of Reproductive Immunology</i> , 2018 , 79, e12801	3.8	2
88	One Size Does Not Fit All: The Effect of Chain Length and Charge Density of Poly(ethylene imine) Based Copolymers on Delivery of pDNA, mRNA, and RepRNA Polyplexes. <i>Biomacromolecules</i> , 2018 , 19, 2870-2879	6.9	35
87	Unexpected synergistic HIV neutralization by a triple microbicide produced in rice endosperm. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E7854-E7862	11.5	20
86	Molecular Signatures of a TLR4 Agonist-Adjuvanted HIV-1 Vaccine Candidate in Humans. <i>Frontiers in Immunology</i> , 2018 , 9, 301	8.4	16
85	The Multifaceted Nature of Immunoglobulin A and Its Complex Role in HIV. <i>AIDS Research and Human Retroviruses</i> , 2018 , 34, 727-738	1.6	11
84	Structural Components for Amplification of Positive and Negative Strand VEEV Splitzicons. <i>Frontiers in Molecular Biosciences</i> , 2018 , 5, 71	5.6	15
83	Rational Design of DNA-Expressed Stabilized Native-Like HIV-1 Envelope Trimers. <i>Cell Reports</i> , 2018 , 24, 3324-3338.e5	10.6	33
82	Intravaginal immunisation using a novel antigen-releasing ring device elicits robust vaccine antigen-specific systemic and mucosal humoral immune responses. <i>Journal of Controlled Release</i> , 2017 , 249, 74-83	11.7	15

81	Flow virometry analysis of envelope glycoprotein conformations on individual HIV virions. <i>Scientific Reports</i> , 2017 , 7, 948	4.9	16
80	The synergistic effects of combining TLR ligand based adjuvants on the cytokine response are dependent upon p38/JNK signalling. <i>Cytokine</i> , 2017 , 99, 287-296	4	19
79	Isolation and Characterization of Antigen-Specific Plasmablasts Using a Novel Flow Cytometry-Based Ig Capture Assay. <i>Journal of Immunology</i> , 2017 , 199, 4180-4188	5.3	15
78	Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies. <i>Journal of Virology</i> , 2017 , 91,	6.6	21
77	A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes. <i>Frontiers in Immunology</i> , 2017 , 8, 149	8.4	19
76	A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine Regimens. <i>Frontiers in Immunology</i> , 2017 , 8, 595	8.4	13
75	Innate activation of human primary epithelial cells broadens the host response to Mycobacterium tuberculosis in the airways. <i>PLoS Pathogens</i> , 2017 , 13, e1006577	7.6	31
74	HIV-1 CNS in vitro infectivity models based on clinical CSF samples. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 235-43	5.1	6
73	Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016 , 73, 252-257	3.1	18
72	Infection of rhesus macaques with a pool of simian immunodeficiency virus with the envelope genes from acute HIV-1 infections. <i>AIDS Research and Therapy</i> , 2016 , 13, 41	3	3
71	CD71 targeting boosts immunogenicity of sublingually delivered influenza haemagglutinin antigen and protects against viral challenge in mice. <i>Journal of Controlled Release</i> , 2016 , 232, 75-82	11.7	4
70	Immune Activation in the Female Genital Tract: Expression Profiles of Soluble Proteins in Women at High Risk for HIV Infection. <i>PLoS ONE</i> , 2016 , 11, e0143109	3.7	41
69	TLR4 and TLR7/8 Adjuvant Combinations Generate Different Vaccine Antigen-Specific Immune Outcomes in Minipigs when Administered via the ID or IN Routes. <i>PLoS ONE</i> , 2016 , 11, e0148984	3.7	26
68	Expression Profile of Human Fc Receptors in Mucosal Tissue: Implications for Antibody-Dependent Cellular Effector Functions Targeting HIV-1 Transmission. <i>PLoS ONE</i> , 2016 , 11, e0154656	3.7	17
67	Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study. <i>PLoS ONE</i> , 2016 , 11, e0152038	3.7	26
66	Short Communication: Limited Anti-HIV-1 Activity of Maraviroc in Mucosal Tissues. <i>AIDS Research and Human Retroviruses</i> , 2016 , 32, 334-8	1.6	9
65	Rice endosperm is cost-effective for the production of recombinant griffithsin with potent activity against HIV. <i>Plant Biotechnology Journal</i> , 2016 , 14, 1427-37	11.6	29
64	Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates. <i>Journal of Virology</i> , 2016 , 90, 5315-5328	6.6	7

63	Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9. <i>Journal of General Virology</i> , 2015 , 96, 2381-2393	4.9	133
62	Tetherin restricts HSV-2 release and is counteracted by multiple viral glycoproteins. <i>Virology</i> , 2015 , 475, 96-109	3.6	20
61	Infection of ectocervical tissue and universal targeting of T-cells mediated by primary non-macrophage-tropic and highly macrophage-tropic HIV-1 R5 envelopes. <i>Retrovirology</i> , 2015 , 12, 48	3.6	4
60	Discrete partitioning of HIV-1 Env forms revealed by viral capture. <i>Retrovirology</i> , 2015 , 12, 81	3.6	12
59	Intramuscular Immunisation with Chlamydial Proteins Induces Chlamydia trachomatis Specific Ocular Antibodies. <i>PLoS ONE</i> , 2015 , 10, e0141209	3.7	19
58	Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. <i>PLoS Pathogens</i> , 2015 , 11, e1005042	7.6	111
57	Evaluation of mucosal adjuvants and immunization routes for the induction of systemic and mucosal humoral immune responses in macaques. <i>Human Vaccines and Immunotherapeutics</i> , 2015 , 11, 2913-22	4.4	13
56	HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial. <i>PLoS ONE</i> , 2015 , 10, e0131748	3.7	32
55	Plasmid DNA Vaccine Co-Immunisation Modulates Cellular and Humoral Immune Responses Induced by Intranasal Inoculation in Mice. <i>PLoS ONE</i> , 2015 , 10, e0141557	3.7	6
54	Enhanced immunogenicity of an HIV-1 DNA vaccine delivered with electroporation via combined intramuscular and intradermal routes. <i>Journal of Virology</i> , 2014 , 88, 6959-69	6.6	25
53	Polymeric penetration enhancers promote humoral immune responses to mucosal vaccines. <i>Journal of Controlled Release</i> , 2014 , 183, 43-50	11.7	20
52	Combinations of TLR4 and TLR7/8 Adjuvants Administered via the ID or IN Routes Generate Different Vaccine Antigen-specific Immune Outcomes in Minipigs. <i>AIDS Research and Human Retroviruses</i> , 2014 , 30, A194-A195	1.6	
51	Intradermal HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees. <i>AIDS Research and Human Retroviruses</i> , 2014 , 30, A31-A32	1.6	
50	Functional Assessment of Antibody Activity in Mucosal Tissue Explant and Cellular Inhibition Assays. <i>AIDS Research and Human Retroviruses</i> , 2014 , 30, A230-A230	1.6	
49	A Phase I Clinical Trial with a Novel gp41 HIV Vaccine (EN41-FPA2) in Healthy Female Volunteers: A Mucosal Prime and Intramuscular Boost Regimen. <i>AIDS Research and Human Retroviruses</i> , 2014 , 30, A187-A188	1.6	
48	Aggregate complexes of HIV-1 induced by multimeric antibodies. <i>Retrovirology</i> , 2014 , 11, 78	3.6	22
47	Capacity for infectious HIV-1 virion capture differs by envelope antibody specificity. <i>Journal of Virology</i> , 2014 , 88, 5165-70	6.6	34
46	Exploring Innovative Approaches to the Formulation of Microbicides to Boost Antiretroviral Drug Delivery and Activity at Mucosal Sites. <i>AIDS Research and Human Retroviruses</i> , 2014 , 30, A150-A151	1.6	

45	Knowing Whom We Are trying to Protect: An Assessment of HIV Risk in South African Adolescent Females. <i>AIDS Research and Human Retroviruses</i> , 2014 , 30, A131-A131	1.6	1
44	Candidate microbicides and their mechanisms of action. <i>Current Topics in Microbiology and Immunology</i> , 2014 , 383, 1-25	3.3	11
43	Glucopyranosyl lipid A adjuvant significantly enhances HIV specific T and B cell responses elicited by a DNA-MVA-protein vaccine regimen. <i>PLoS ONE</i> , 2014 , 9, e84707	3.7	29
42	Dynamic electrophoretic fingerprinting of the HIV-1 envelope glycoprotein. <i>Retrovirology</i> , 2013 , 10, 33	3.6	10
41	Pulmonary delivery of DNA vaccine constructs using deacylated PEI elicits immune responses and protects against viral challenge infection. <i>Journal of Controlled Release</i> , 2013 , 170, 452-9	11.7	28
40	Mucosal tissue tropism and dissemination of HIV-1 subtype B acute envelope-expressing chimeric virus. <i>Journal of Virology</i> , 2013 , 87, 890-9	6.6	21
39	CCL19 and CCL28 augment mucosal and systemic immune responses to HIV-1 gp140 by mobilizing responsive immunocytes into secondary lymph nodes and mucosal tissue. <i>Journal of Immunology</i> , 2013 , 191, 1935-47	5.3	36
38	Neutralizing IgG at the portal of infection mediates protection against vaginal simian/human immunodeficiency virus challenge. <i>Journal of Virology</i> , 2013 , 87, 11604-16	6.6	38
37	A "prime-pull" vaccine strategy has a modest effect on local and systemic antibody responses to HIV gp140 in mice. <i>PLoS ONE</i> , 2013 , 8, e80559	3.7	15
36	Mucosal application of gp140 encoding DNA polyplexes to different tissues results in altered immunological outcomes in mice. <i>PLoS ONE</i> , 2013 , 8, e67412	3.7	16
35	Highly conserved HIV-1 gp120 glycans proximal to CD4-binding region affect viral infectivity and neutralizing antibody induction. <i>Virology</i> , 2012 , 423, 97-106	3.6	45
34	Thymic stromal lymphopoietin (TSLP) acts as a potent mucosal adjuvant for HIV-1 gp140 vaccination in mice. <i>European Journal of Immunology</i> , 2012 , 42, 353-63	6.1	30
33	Microneedle mediated intradermal delivery of adjuvanted recombinant HIV-1 CN54gp140 effectively primes mucosal boost inoculations. <i>Journal of Controlled Release</i> , 2012 , 162, 529-37	11.7	64
32	HIV-1 expressing the envelopes of transmitted/founder or control/reference viruses have similar infection patterns of CD4 T-cells in human cervical tissue ex vivo. <i>PLoS ONE</i> , 2012 , 7, e50839	3.7	15
31	MiniCD4 microbicide prevents HIV infection of human mucosal explants and vaginal transmission of SHIV(162P3) in cynomolgus macaques. <i>PLoS Pathogens</i> , 2012 , 8, e1003071	7.6	29
30	Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140. <i>PLoS ONE</i> , 2012 , 7, e41144	3.7	75
29	Potential use of protease inhibitors as vaginal and colorectal microbicides. <i>Current HIV Research</i> , 2012 , 10, 42-52	1.3	15
28	Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 2251-8	5.9	52

27	Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. <i>Journal of Virology</i> , 2012 , 86, 2715-28	6.6	239
26	Evaluation of TLR agonists as potential mucosal adjuvants for HIV gp140 and tetanus toxoid in mice. <i>PLoS ONE</i> , 2012 , 7, e50529	3.7	46
25	Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen. <i>Vaccine</i> , 2011 , 29, 1258-69	4.1	30
24	Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation. <i>Vaccine</i> , 2011 , 29, 1421-30	4.1	34
23	Intravaginal immunization using the recombinant HIV-1 clade-C trimeric envelope glycoprotein CN54gp140 formulated within lyophilized solid dosage forms. <i>Vaccine</i> , 2011 , 29, 4512-20	4.1	21
22	A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment. <i>PLoS ONE</i> , 2011 , 6, e15861	3.7	9
21	Phase I randomised clinical trial of an HIV-1(CN54), clade C, trimeric envelope vaccine candidate delivered vaginally. <i>PLoS ONE</i> , 2011 , 6, e25165	3.7	40
20	AIDS. Turning the tide against HIV. <i>Science</i> , 2011 , 333, 42-3	33.3	64
19	Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines. <i>Antiviral Research</i> , 2010 , 88 Suppl 1, S55-66	10.8	69
18	Multisite comparison of anti-human immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysis. <i>Journal of Clinical Microbiology</i> , 2009 , 47, 3530-9	9.7	40
17	Reverse transcriptase inhibitors as potential colorectal microbicides. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 1797-807	5.9	68
16	HIV-1 infection of human penile explant tissue and protection by candidate microbicides. <i>Aids</i> , 2009 , 23, 319-28	3.5	80
15	Critical issues in mucosal immunity for HIV-1 vaccine development. <i>Journal of Allergy and Clinical Immunology</i> , 2008 , 122, 3-9; quiz 10-1	11.5	56
14	Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study. <i>Analytical Chemistry</i> , 2008 , 80, 4741-51	7.8	136
13	Improving defences at the portal of HIV entry: mucosal and innate immunity. <i>PLoS Medicine</i> , 2008 , 5, e81	11.6	46
12	Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. <i>PLoS Medicine</i> , 2008 , 5, e157; discussion e157	11.6	121
11	In vitro and in vivo: the story of nonoxynol 9. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005 , 39, 1-8	3.1	167
10	The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells. <i>Journal of Virology</i> , 2005 , 79, 11179-86	6.6	85

9	Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. <i>Journal of Experimental Medicine</i> , 2004 , 199, 1065-75	16.6	198
8	Microbicides--aids to safer sex. <i>Lancet, The</i> , 2004 , 363, 1002-3	40	41
7	Inhibiting sexual transmission of HIV-1 infection. <i>Nature Reviews Microbiology</i> , 2003 , 1, 25-34	22.2	419
6	In vitro models of mucosal HIV transmission. <i>Nature Medicine</i> , 2000 , 6, 607-8	50.5	35
5	Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. <i>Journal of Virology</i> , 2000 , 74, 5577-86	6.6	287
4	Macrophages are the major target cell for HIV infection in long-term marrow culture and demonstrate dual susceptibility to lymphocytotropic and monocytotropic strains of HIV-1. <i>British Journal of Haematology</i> , 1996 , 93, 30-7	4.5	18
3	Evaluation of the Abbott Architect, Roche Elecsys and Virtus S1 SARS-CoV-2 antibody tests in community-managed COVID-19 cases		1
2	Design-of-Experiments In Vitro Transcription Yield Optimization of Self-Amplifying RNA		2
1	Heterologous vaccination regimens with self-amplifying RNA and Adenoviral COVID vaccines induce robust immune responses in mice		5